Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings (in partnership with medwireNews).
From 2021 San Antonio Breast Cancer Symposium:
Latest overall survival findings from the PHOEBE trial support the use of pyrotinib plus capecitabine for second-line care of patients with HER2-positive metastatic breast cancer
From 2021 San Antonio Breast Cancer Symposium:
Monitoring blood levels of ESR1 resistance mutations in metastatic breast cancer patients facilitates a prompt switch from aromatase inhibitor therapy to fulvestrant
From 2021 San Antonio Breast Cancer Symposium:
Hormone receptor-positive early breast cancer patients without diabetes do not benefit from the addition of metformin to postoperative care
From 2021 San Antonio Breast Cancer Symposium:
Metastatic breast cancer patients given a targeted therapy based on ESCAT tier I or II alterations after induction chemotherapy have better progression-free survival than those continuing with maintenance chemotherapy
From the ESMO Congress 2021:
Health-related quality of life and symptom scores are maintained in patients with clear cell renal cell carcinoma taking adjuvant pembrolizumab
From the ESMO Congress 2021:
REGISTRI Results Reported For First-line Regorafenib In KIT/PDGFR Wild-Type Metastatic GIST
From the ESMO Congress 2021:
Plinabulin plus docetaxel survival and safety results support second- or third-line use in non-small-cell lung cancer patients with wild-type EGFR after platinum-based chemotherapy
From the ESMO Congress 2021:
Ipilimumab–nivolumab given every 12 weeks, instead of every 3 weeks, reduces toxicities in patients with treatment-naïve advanced renal cell carcinoma without compromising efficacy
From the ESMO Congress 2021:
The CAPTURE study has characterised functional immune responses in people with cancer following SARS-CoV-2 infection or vaccination
From the ESMO Congress 2021:
People with colorectal cancer liver cancer metastases that have progressed may benefit from second-line trans-arterial Yttrium-90 radioembolisation
From the ESMO Congress 2021:
Most solid tumour patients recently given chemotherapy and/or immunotherapy will achieve an adequate antibody response to COVID-19 vaccination
From the ESMO Congress 2021:
Study findings suggest that drug-free intervals during sunitinib or pazopanib treatment may be acceptable for patients with advanced clear cell renal cell carcinoma
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
